Oneness Biotech Co., Ltd. (LUX: ONES)

Market Cap	1.46B
Revenue (ttm)	3.17M
Net Income (ttm)	-35.53M
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 43
• Stock Exchange: Luxembourg Stock Exchange
• Ticker Symbol: ONES

Financial Performance

Financial numbers in TWD